脑脊液标志物分析在中枢神经系统白血病中的应用研究进展

doi:10.3969/j.issn.1673-8640.2022.05.017

摘要/Abstract

摘要：

近年来,随着治疗方案的改进和新药的应用,白血病的完全缓解率得到明显提高,但仍有许多患者出现复发,合并中枢神经系统白血病（CNSL）是重要的原因之一,患者往往预后较差。目前,CNSL的诊断主要依赖于实验室检查和临床症状。文章介绍了脑脊液常规检查（脑脊液压力、细胞学涂片和生化指标检验）、流式细胞免疫分型等传统方法及其他生物标志物、核酸分子诊断、代谢组学等新技术。这些方法学的临床应用有望提高CNSL诊断的敏感性和特异性,辅助临床进一步早期确诊中枢神经系统受累,并采取有效的预防和干预措施,改善患者预后。

关键词: 中枢神经系统白血病, 脑脊液, 代谢组学

Abstract:

In the recent years,with the improvement of treatment regimens and the application of new drugs,the rate of complete remission of leukemia has been significantly improved. However,many patients still experience relapse,the combination of central nervous system leukemia（CNSL） is an important cause,and the patients often have a poor prognosis. At present,the diagnosis of CNSL mainly relies on clinical laboratory tests and clinical symptoms and signs. This review focuses on not only the traditional tools used to determine clinical samples,including routine cerebrospinal fluid examination（cerebrospinal fluid pressure,cytological smear and biochemical tests）,cerebrospinal fluid flow cytometric immunophenotyping,but also an overview of other biomarkers,nucleic acid molecular diagnostics,metabolomics and other new technologies. These methodologies are expected to improve the sensitivity and specificity of the diagnosis of CNSL,to assist in the early diagnosis of central nervous system involvement,and to improve the clinical prognosis of patients by taking effective preventive and intervention measures.

Key words: Central nervous system leukemia, Cerebrospinal fluid, Metabolomics

王勉, 杨建民, 宋志强, 唐古生. 脑脊液标志物分析在中枢神经系统白血病中的应用研究进展[J]. 检验医学, 2022, 37(5): 483-488.

WANG Mian, YANG Jianmin, SONG Zhiqiang, TANG Gusheng. Research progress in the application of cerebrospinal fluid marker analysis in central nervous system leukemia[J]. Laboratory Medicine, 2022, 37(5): 483-488.

参考文献 40

[1]	LAZARUS H M, RICHARDS S M, CHOPRA R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis:results from the international ALL trial MRC UKALL XII/ECOG E2993[J]. Blood, 2006, 108(2):465-472.
[2]	THASTRUP M, MARQUART H V, LEVINSEN M, et al. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia:a Nordic Society of Pediatric Hematology and Oncology study[J]. Leukemia, 2020, 34(2):336-346. DOI URL
[3]	LEVINSEN M, MARQUART H V, GROTH-PEDERSEN L, et al. Leukemic blasts are present at low levels in spinal fluid in one-third of childhood acute lymphoblastic leukemia cases[J]. Pediatr Blood Cancer, 2016, 63(11):1935-1942. DOI URL
[4]	YAO H, PRICE T T, CANTELLI G, et al. Leukaemia hijacks a neural mechanism to invade the central nervous system[J]. Nature, 2018, 560(7716):55-60. DOI URL
[5]	HEGDE U, FILIE A, LITTLE R F, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement:the role of flow cytometry versus cytology[J]. Blood, 2005, 105(2):496-502. DOI URL
[6]	BIOJONE E, QUEIRÓZ RDE P, VALERA E T, et al. Minimal residual disease in cerebrospinal fluid at diagnosis:a more intensive treatment protocol was able to eliminate the adverse prognosis in children with acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2012, 53(1):89-95. DOI URL
[7]	PUI C H, THIEL E. Central nervous system disease in hematologic malignancies:historical perspective and practical applications[J]. Semin Oncol, 2009, 36(4 Suppl 2):S2-S16. DOI URL
[8]	陈亚峰, 黄文娟, 金玲, 等. 中枢神经系统白血病脑脊液蛋白质、氯化物、糖定量变化分析[J]. 现代诊断与治疗, 2014, 259(21):4952-4953.
[9]	RAO D, GHALAUT V S, GHALAUT P S, et al. Case series:CSF LDH,proteins and electrolyte levels in patients of acute lymphocytic leukemia[J]. Clin Chim Acta, 2012, 413(13-14):1045-1048. DOI URL
[10]	王文静, 高文婷, 李梦雪, 等. 脑脊液中β_2-微球蛋白、超氧化物歧化酶、铁蛋白检测在中枢神经系统白血病诊断中的应用价值[J]. 国际检验医学杂志, 2020, 41(5):592-595.
[11]	LIANG Y, CA Q, ZHAI Z M, et al. A practical strategy of monitoring minimal residue disease and intervention for central nervous system relapse of childhood acute lymphoblastic leukemia:a single Chinese center's experience[J]. J Pediatr Hematol Oncol, 2013, 35(5):388-393. DOI URL
[12]	DEL PRINCIPE M I, BUZZATTI E, PICIOCCHI A, et al. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network[J]. Haematologica, 2021, 106(1):39-45. DOI URL
[13]	翁香琴, 王莉莉. 多参数流式细胞术检测急性白血病及浆细胞肿瘤微小残留病中国专家共识(2017年版)[J]. 中华血液学杂志, 2017, 38(12):1001-1011.
[14]	GABELLI M, DISARÒ S, SCARPARO P, et al. Cerebrospinal fluid analysis by 8-color flow cytometry in children with acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2019, 60(11):2825-2828. DOI URL
[15]	BROMBERG J E, BREEMS D A, KRAAN J, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies[J]. Neurology, 2007, 68(20):1674-1679. DOI URL
[16]	BENTO L C, CORREIA R P, ALEXANDRE A M, et al. Detection of central nervous system infiltration by myeloid and lymphoid hematologic neoplasms using flow cytometry analysis:diagnostic accuracy study[J]. Front Med(Lausanne), 2018, 5:70.
[17]	CIVINI S, JIN P, REN J, et al. Leukemia cells induce changes in human bone marrow stromal cells[J]. J Transl Med, 2013, 11:298. DOI URL
[18]	ENGSIG M T, CHEN Q J, VU T H, et al. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones[J]. J Cell Biol, 2000, 151(4):879-889. DOI URL
[19]	WONG E T, ALSOP D, LEE D, et al. Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas[J]. Cerebrospinal Fluid Res, 2008, 5:1. DOI URL
[20]	杨华, 沈立云, 杜幸军, 等. 中枢神经系统白血病脑脊液MMP-2和TIMP-2测定的临床意义[J]. 中国实用神经疾病杂志, 2016, 19(18):47-48.
[21]	TUN H W, PERSONETT D, BASKERVILLE K A, et al. Pathway analysis of primary central nervous system lymphoma[J]. Blood, 2008, 111(6):3200-3210. DOI URL
[22]	VAN DER VELDEN V H, DE LAUNAIJ D, DE VRIES J F, et al. New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B-cell precursor acute lymphoblastic leukaemia[J]. Br J Haematol, 2016, 172(5):769-781. DOI URL
[23]	TANG Y T, JIANG F, GUO L, et al. The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis[J]. J Neurooncol, 2013, 112(3):329-338. DOI URL
[24]	ROBERTS T K, EUGENIN E A, LOPEZ L, et al. CCL2 disrupts the adherens junction:implications for neuroinflammation[J]. Lab Invest, 2012, 92(8):1213-1233. DOI URL
[25]	SI M Y, FAN Z C, LI Y Z, et al. The prognostic significance of serum and cerebrospinal fluid MMP-9,CCL2 and sVCAM-1 in leukemia CNS metastasis[J]. J Neurooncol, 2015, 122(2):229-244. DOI URL
[26]	LEE W, KIM S J, LEE S, et al. Significance of cerebrospinal fluid sIL-2R level as a marker of CNS involvement in acute lymphoblastic leukemia[J]. Ann Clin Lab Sci, 2005, 35(4):407-412.
[27]	OZEKI K, KIYOI H, HIROSE Y, et al. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia[J]. Blood, 2004, 103(5):1901-1908. DOI URL
[28]	李明, 杨新平, 敖绩逃, 等. FLT3基因在中枢神经系统白血病中的表达及意义[J]. 实用医学杂志, 2019, 35(6):940-944.
[29]	RAMIREZ O, LINARES A, TRUJILLO M L, et al. WT1 mRNA in cerebrospinal fluid associated with relapse in pediatric lymphoblastic leukemia[J]. J Pediatr Hematol Oncol, 2003, 25(6):453-458. DOI URL
[30]	SAYED D, BADRAWY H, ALI A M, et al. Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia[J]. Leuk Res, 2009, 33(5):655-661. DOI URL
[31]	PINE S R, YIN C, MATLOUB Y H, et al. Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction[J]. J Mol Diagn, 2005, 7(1):127-132. DOI URL
[32]	HIEMCKE-JIWA L S, LEGUIT R J, SNIJDERS T J, et al. MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma[J]. Br J Haematol, 2019, 185(5):974-977. DOI URL
[33]	HICKMANN A K, FRICK M, HADASCHIK D, et al. Molecular tumor analysis and liquid biopsy:a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas[J]. BMC Cancer, 2019, 19(1):192. DOI URL
[34]	BOBILLO S, CRESPO M, ESCUDERO L, et al. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas[J]. Haematologica, 2021, 106(2):513-521. DOI URL
[35]	ROY S, JOSEPHSON S A, FRIDLYAND J, et al. Protein biomarker identification in the CSF of patients with CNS lymphoma[J]. J Clin Oncol, 2008, 26(1):96-105. DOI URL
[36]	GUO L, REN H, ZENG H, et al. Proteomic analysis of cerebrospinal fluid in pediatric acute lymphoblastic leukemia patients:a pilot study[J]. Onco Targets Ther, 2019, 12:3859-3868. DOI URL
[37]	MO F, MA X, LIU X, et al. Altered CSF proteomic profiling of paediatric acute lymphocytic leukemia patients with CNS infiltration[J]. J Oncol, 2019, 2019:3283629.
[38]	NAKAMIZO S, SASAYAMA T, SHINOHARA M, et al. GC/MS-based metabolomic analysis of cerebrospinal fluid(CSF) from glioma patients[J]. J Neurooncol, 2013, 113(1):65-74. DOI URL
[39]	PLOESSL K, WANG L, LIEBERMAN B P, et al. Comparative evaluation of 18F-labeled glutamic acid and glutamine as tumor metabolic imaging agents[J]. J Nucl Med, 2012, 53(10):1616-1624. DOI URL
[40]	ERB U, SCHWERK C, SCHROTEN H, et al. Review of functional in vitro models of the blood-cerebrospinal fluid barrier in leukaemia research[J]. J Neurosci Methods, 2020, 329:108478. DOI URL